Therapeutics for Inflammatory Diseases: Current Challenges and Future Market

리서치사	BCC Research
발행일	2006년 03월	상품코드	37485
페이지 정보	183 pages 44 tables
가격	US $ 4,850 ￦ 5,778,700 PDF by E-mail (Single User License)

한글목차
영문목차
관련자료

영문목차

Abstract

REPORT HIGHLIGHTS

The market for anti-inflammatory drugs to treat the diseases covered in this report was approximately $31.1 billion in 2005 and is projected to increase to $47.8 billion in 2010.
The fastest growing disease category for anti-inflammatory treatment is psoriasis, which saw the first introductions of expensive monoclonal antibody products in the last two years.
The largest market by far in 2005 is that for the treatment of asthma and chronic obstructive pulmonary disease, which accounted for approximately 53.4% of the total markets covered in this report. The asthma/COPD market will remain the largest in 2010, but its market share will decline to 47.9% of the total of markets covered.

INTRODUCTION

The anti-inflammatory products market was dramatically shaken in September 2004 with the withdrawal from the marketplace of Merck갽s multibillion-dollar anti-inflammatory drug Vioxx. This was followed by the withdrawal of another cyclooxygenase-2 (COX-2) inhibiting anti-inflammatory product, Pfi zer갽s Bextra, from the American, Canadian and European markets in April 2005. This left only one COX-2 inhibitor, Pfi zer갽s Celebrex, on the U.S. market. Following the removal of Vioxx, the U.S. Food and Drug Administration (FDA) enhanced its scrutiny of this class of drugs and required black-box warnings to be placed on all similar prescription and nonprescription nonsteroidal anti-inflammatory drugs (NSAIDs).

SCOPE OF STUDY

This comprehensive study:

Analyzes and assesses marketed and in-development prescription, systemic anti-infl ammatory drugs indicated for the following diseases—ankylosing spondylitis, asthma/chronic obstructive pulmonary disease (COPD), infl ammatory bowel diseases, multiple sclerosis, psoriasis and rheumatoid arthritis.
Provides an overview of the categories of anti-inflammatory drugs, including biological anti-infl ammatory products, their methods of activity, usage and sales. Markets for antiinfl ammatory drugs by disease, including sales and forecasts as well as discussion of products for each indication that are in Phase II and later trials.
Discusses industry structure including the impact of the removal of Vioxx and Bextra from the marketplace Also discussed is the issue of direct-to-consumer (DTC) marketing.
Profiles companies emphasizing leaders in the pharmaceutical and biotechnology industry in the research and development of anti-infl ammatory drugs and the innovative products they have launched or have in development.

METHODOLOGY

The base year for this study is 2005. Figures are based on revenue figures at the manufacturers' level and are projected in 2005 constant dollars; that is, inflation is not computed into the projection figures.

Information to prepare this study was derived from information obtained from product managers, marketing strategists, research executives and others at leading pharmaceutical and biotechnology companies that compete in the market for anti-inflammatory drugs or that have products in development for this market.

INFORMATION SOURCES

The information and analyses presented in this report are based on an extensive survey of the biotechnology and pharmaceutical industries as well as a detailed examination of published literature and reports obtained from regulatory authorities, medical research institutions, pharmaceutical trade associations and national and world health organizations. Key information from the business literature was used to obtain expert opinion on commercial potential and market sizes from industry professionals.

INTRODUCTION
SUMMARY
- Summary Table: GLOBAL MARKET FOR ANTI-INFLAMMATORY TREATMENTSBY TYPE OF DISEASES, THROUGH 2010 ($ MILLIONS)
- Summary Figure: ESTIMATED GLOBAL MARKET SHARE FOR ANTI-INFLAMMATORY TREATMENTS BY SELECTED DISEASES, 2005 AND 2010 (%)
OVERVIEW
- Table 1 MEDIATORS OF INFLAMMATION AND THEIR FUNCTION(S)
- Table 2 COMPLEMENT INHIBITORS IN DEVELOPMENT
- Table 3 CYTOKINES WITH ANTI-INFLAMMATORY ACTIVITY
- Table 4 SOLUBLE CYTOKINE RECEPTORS WITH ANTI-INFLAMMATORY ACTIVITY
- Table 5 CATEGORIES OF CYTOKINES
  - BIOLOGICAL RESPONSE MODIFIERS
- Table 6 COLONY STIMULATING FACTORS AND ERYTHROPOIETIN, THEIR NATURAL SOURCES AND MAJOR EFFECTS
- Table 7 INTERFERONS, THEIR NATURAL SOURCES AND MAJOR EFFECTS
- Table 7 (CONTINUED)
- Table 7 (CONTINUED)
- Table 8 INTERLEUKINS, THEIR NATURAL SOURCES AND MAJOR EFFECTS
- Table 8 (CONTINUED)
- Table 8 (CONTINUED)
- Table 9 TUMOR NECROSIS FACTORS (TNFS), THEIR NATURAL SOURCES AND MAJOR EFFECTS
  - MAJOR ANTI-INFLAMMATORY CYTOKINES WITH THERAPEUTIC INDICATIONS
- Table 10 ANTI-INFLAMMATORY CYTOKINES IN CLINICAL DEVELOPMENT
- Table 11 SUPPRESSORS OF CYTOKINE SIGNALING AND THEIR POTENTIAL THERAPEUTIC AREAS
  - CURRENT PRODUCT CATEGORIES FOR INFLAMMATORY DISEASES
    - ANTIBODY-BASED PRODUCTS
- Table 12 MARKETED MONOCLONAL ANTIBODY PRODUCTS FOR THE TREATMENT OF ANTI-INFLAMMATORY DISEASES
- Table 13 THERAPEUTIC ANTIBODY PRODUCTS IN PHASE II OR LATER DEVELOPMENT FOR THE TREATMENT OF INFLAMMATORY DISEASES
- Table 13 (CONTINUED)
- Table 13 (CONTINUED)
- Table 13 (CONTINUED)
- Table 13 (CONTINUED)
- Table 13 (CONTINUED)
- Table 13 (CONTINUED)
  - DRUGS IN DEVELOPMENT FOR INFLAMMATORY DISEASES
- Table 14 DRUGS IN PHASE II OR LATER DEVELOPMENT FOR THE TREATMENT OF INFLAMMATORY DISEASES
- Table 14 (CONTINUED)
- Table 14 (CONTINUED)
- Table 14 (CONTINUED)
- Table 14 (CONTINUED)
- Table 14 (CONTINUED)
- Table 14 (CONTINUED)
- Table 14 (CONTINUED)
- Table 14 (CONTINUED)
  - TARGETS FOR ANTI-INFLAMMATORY DRUGS
    - NUCLEAR FACTOR KB
    - TOLL-LIKE RECEPTORS
      - Toll-Like Receptors (Continued)
APPLICATIONS AND PRODUCTS
- Table 15 GLOBAL MARKET FOR ANTI-INFLAMMATORY TREATMENTS BY CATEGORY, THROUGH 2010 ($ MILLIONS)
- Figure 1 GLOBAL MARKET FOR ANTI-INFLAMMATORY TREATMENTS BY CATEGORY, 2003-2010 ($ MILLIONS)
- Table 16 CURRENTLY MARKETED NONSTEROIDAL ANTI-INFLAMMATORY DRUGS
- Table 16 (CONTINUED)
- Table 17 GLOBAL MARKET FOR COX-2 INHIBITORS BY PRODUCT, THROUGH 2010 ($ MILLIONS)
- Figure 2 GLOBAL MARKET FOR COX-2 INHIBITORS BY PRODUCT, 2003-2010 ($ MILLIONS)
- Table 18 U.S. MARKET FOR COX-2 INHIBITORS BY PRODUCT, THROUGH 2010 ($ MILLIONS)
- Figure 3 U.S. MARKET FOR COX-2 INHIBITORS BY PRODUCT, 2003-2010 ($ MILLIONS)
- Table 19 GLOBAL MARKET FOR ANTI-INFLAMMATORY TREATMENTS FOR ANKYLOSING SPONDYLITIS, THROUGH 2010 ($ MILLIONS)
- Table 20 ASTHMA DRUG CATEGORIES AND SELECTED PRODUCTS
- Table 20 (CONTINUED)
- Table 21 SELECTED BRANDED ANTI-INFLAMMATORY AND BRONCHODILATING DRUGS USED TO TREAT ASTHMA
- Table 21 (CONTINUED)
- Table 22 GLOBAL MARKET FOR ASTHMA DRUGS BY CATEGORY, THROUGH 2010 ($ MILLIONS)
- Figure 4 GLOBAL MARKET FOR ASTHMA DRUGS BY CATEGORY, 2003-2010 ($ MILLIONS)
- Table 23 GLOBAL MARKET FOR ANTI-INFLAMMATORY DRUGS USED TO TREAT ASTHMA BY CATEGORY, THROUGH 2010 ($ MILLIONS)
- Figure 5 GLOBAL MARKET FOR ANTI-INFLAMMATORY DRUGS USED TO TREAT ASTHMA BY CATEGORY, 2003-2010 ($ MILLIONS)
- Table 24 U.S. MARKET FOR ASTHMA DRUGS BY CATEGORY, THROUGH 2010 ($ MILLIONS)
- Figure 6 U.S. MARKET FOR ASTHMA DRUGS BY CATEGORY, 2003-2010 ($ MILLIONS)
- Table 25 GLOBAL MARKET FOR COPD DRUGS BY CATEGORY, THROUGH 2010 ($ MILLIONS)
- Figure 7 GLOBAL MARKET FOR COPD DRUGS BY CATEGORY, 2003-2010 ($ MILLIONS)
- Table 26 GLOBAL MARKET FOR ANTI-INFLAMMATORY DRUGS USED TO TREAT COPD BY CATEGORY, 2003-2010 ($ MILLIONS)
- Figure 8 GLOBAL MARKET FOR ANTI-INFLAMMATORY DRUGS USED TO TREAT COPD BY CATEGORY, 2003-2010 ($ MILLIONS)
- Figure 9 ESTIMATED GLOBAL MARKET SHARE FOR ANTI-INFLAMMATORY DRUGS TO TREAT ASTHMA/COPD, BY CATEGORY, 2005 AND 2010 (%)
- Table 27 PHOSPHODIESTERASE INHIBITORS IN PHASE II OR LATE DEVELOPMENT
- Table 28 TARGETS AND APPROACHES TO THE DEVELOPMENT OF ANTI- INFLAMMATORY DRUGS TO TREAT ASTHMA
- Table 29 GLOBAL MARKET FOR ANTI-INFLAMMATORY TREATMENTS FOR INFLAMMATORY BOWEL DISEASE BY CATEGORY, THROUGH 2010 ($ MILLIONS)
- Figure 10 GLOBAL MARKET FOR ANTI-INFLAMMATORY TREATMENTS FOR INFLAMMATORY BOWEL DISEASE BY CATEGORY, 2003-2010 ($ MILLIONS)
- Table 30 BIOLOGICAL RESPONSE MODIFIERS IN PHASE II OR LATER DEVELOPMENT FOR THE TREATMENT OF CROHNS DISEASE
- Table 31 GLOBAL MARKET FOR ANTICYTOKINE ANTI- INFLAMMATORY TREATMENTS FOR MULTIPLE SCLEROSIS, THROUGH 2010 ($ MILLIONS)
- Table 32 GLOBAL MARKET FOR ANTI-INFLAMMATORY TREATMENTS FOR PSORIASIS, BY CATEGORY, THROUGH 2010 ($ MILLIONS)
- Figure 11 GLOBAL MARKET FOR ANTI-INFLAMMATORY TREATMENTS FOR PSORIASIS, BY CATEGORY, THROUGH 2010 ($ MILLIONS)
- Table 33 COMMONLY USED DMARDS FOR THE TREATMENT OF RHEUMATOID ARTHRITIS
- Table 34 CURRENTLY AVAILABLE BIOLOGIC PRODUCTS FOR THE TREATMENT OF RHEUMATOID ARTHRITIS
- Figure 12 CATEGORIES OF DRUGS USED IN CONJUNCTION WITH TNF-ALPHA INHIBITORS (%)
- Table 35 GLOBAL MARKET FOR MARKETED TNF-ALPHA INHIBITING PRODUCTS FOR ALL INDICATIONS, THROUGH 2010 ($ MILLIONS)
- Figure 13 GLOBAL MARKET FOR MARKETED TNF-ALPHA INHIBITING PRODUCTS FOR ALL INDICATIONS, 2003-2010 ($ MILLIONS)
- Table 36 GLOBAL MARKET FOR ANTI-INFLAMMATORY TREATMENTS FOR RHEUMATOID ARTHRITIS BY CATEGORY, THROUGH 2010 ($ MILLIONS)
- Figure 14 GLOBAL MARKET FOR ANTI-INFLAMMATORY TREATMENTS FOR RHEUMATOID ARTHRITIS BY CATEGORY, 2003-2010 ($ MILLIONS)
- Table 37 GLOBAL MARKET FOR ANTI-INFLAMMATORY TREATMENTS FOR RHEUMATOID ARTHRITIS BY REGION, THROUGH 2010 ($ MILLIONS)
- Figure 15 GLOBAL MARKET FOR ANTI-INFLAMMATORY TREATMENTS FOR RHEUMATOID ARTHRITIS BY REGION, 2003-2010 ($ MILLIONS)
- Figure 16 ESTIMATED GLOBAL PRESCRIPTION MARKET SHARE FOR ANTI-INFLAMMATORY TREATMENTS FOR RHEUMATOID ARTHRITIS, BY CATEGORY, 2005 (%)
- Table 38 PRODUCTS IN PHASE II OR LATER DEVELOPMENT FOR THE TREATMENT OF RHEUMATOID ARTHRITIS
- Table 38 (CONTINUED)
- Table 38 (CONTINUED)
INDUSTRY
COMPANY PROFILES
- Table 39 AMGENS ANTI-INFLAMMATORY PRODUCT PIPELINE
  - BIOGEN IDEC, INC.
    - BUSINESS OVERVIEW
    - FINANCIAL INFORMATION
    - PRODUCTS
- Table 40 BIOGEN IDECS ANTI-INFLAMMATORY PRODUCT PIPELINE
  - CAMBRIDGE ANTIBODY TECHNOLOGY GROUP PLC
    - BUSINESS OVERVIEW
    - PRODUCTS
- Table 41 CAMBRIDGE ANTIBODY TECHNOLOGYS ANTI-INFLAMMATORY PRODUCT PIPELINE
  - CELGENE CORPORATION
    - BUSINESS OVERVIEW
    - PRODUCTS
    - FINANCIAL INFORMATION
    - CORPORATE STRATEGY
  - DYNAVAX TECHNOLOGIES CORPORATION
    - BUSINESS OVERVIEW
    - FINANCIAL INFORMATION
    - PRODUCTS IN DEVELOPMENT
    - CORPORATE STRATEGY
  - EPIGENESIS PHARMACEUTICALS
    - BUSINESS OVERVIEW
    - PRODUCTS IN DEVELOPMENT
    - CORPORATE STRATEGY
  - GENENTECH, INC.
    - BUSINESS OVERVIEW
    - FINANCIAL INFORMATION
    - PRODUCTS
    - CORPORATE STRATEGY
  - GENMAB A/S
    - BUSINESS OVERVIEW
    - PRODUCTS
    - CORPORATE STRATEGY
  - GLAXOSMITHKLINE PLC
    - BUSINESS OVERVIEW
    - FINANCIAL INFORMATION
    - PRODUCTS
- Table 42 GLAXOSMITHKLINES ANTI-INFLAMMATORY PRODUCT PIPELINE
- Table 42 (CONTINUED)
  - ISIS PHARMACEUTICALS, INC.
    - BUSINESS OVERVIEW
    - FINANCIAL INFORMATION
    - PRODUCTS
    - CORPORATE STRATEGY
  - MILLENNIUM PHARMACEUTICALS, INC.
    - BUSINESS OVERVIEW
    - FINANCIAL INFORMATION
    - PRODUCTS
- Table 43 MILLENNIUMS ANTI-INFLAMMATORY MONOCLONAL ANTIBODY PRODUCT PIPELINE
  - NOVARTIS AG
    - BUSINESS OVERVIEW
    - FINANCIAL INFORMATION
    - PRODUCTS
  - PROTEIN DESIGN LABS
    - BUSINESS OVERVIEW
    - FINANCIAL INFORMATION
    - PRODUCTS
- Table 44 PROTEIN DESIGN LABS ANTI-INFLAMMATORY MONOCLONAL ANTIBODY PRODUCT PIPELINE
  - REGENERON PHARMACEUTICALS, INC.
    - BUSINESS OVERVIEW
    - FINANCIAL INFORMATION
    - PRODUCT CANDIDATES
    - CORPORATE STRATEGY
  - SCHERING-PLOUGH CORPORATION
    - BUSINESS OVERVIEW
    - FINANCIAL INFORMATION
    - PRODUCTS
    - CORPORATE STRATEGY
LIST OF TABLES
Summary Table:
Table 1 MEDIATORS OF INFLAMMATION AND THEIR FUNCTION(S)
Table 2 COMPLEMENT INHIBITORS IN DEVELOPMENT
Table 3 CYTOKINES WITH ANTI-INFLAMMATORY ACTIVITY
Table 4 SOLUBLE CYTOKINE RECEPTORS WITH ANTI-INFLAMMATORY ACTIVITY
Table 5 CATEGORIES OF CYTOKINES
Table 6 COLONY STIMULATING FACTORS AND ERYTHROPOIETIN, THEIR NATURAL SOURCES AND MAJOR EFFECTS
Table 7 INTERFERONS, THEIR NATURAL SOURCES AND MAJOR EFFECTS
Table 8 INTERLEUKINS, THEIR NATURAL SOURCES AND MAJOR EFFECTS
Table 9 TUMOR NECROSIS FACTORS (TNFS), THEIR NATURAL SOURCES AND MAJOR EFFECTS
Table 10 ANTI-INFLAMMATORY CYTOKINES IN CLINICAL DEVELOPMENT
Table 11 SUPPRESSORS OF CYTOKINE SIGNALING AND THEIR POTENTIAL THERAPEUTIC AREAS
Table 12 MARKETED MONOCLONAL ANTIBODY PRODUCTS FOR THE TREATMENT OF ANTI-INFLAMMATORY DISEASES
Table 13 THERAPEUTIC ANTIBODY PRODUCTS IN PHASE II OR LATER DEVELOPMENT FOR THE TREATMENT OF INFLAMMATORY DISEASES
Table 14 DRUGS IN PHASE II OR LATER DEVELOPMENT FOR THE TREATMENT OF INFLAMMATORY DISEASES
Table 15 GLOBAL MARKET FOR ANTI-INFLAMMATORY TREATMENTS BY CATEGORY, THROUGH 2010 ($ MILLIONS)
Table 16 CURRENTLY MARKETED NONSTEROIDAL ANTI-INFLAMMATORY DRUGS
Table 17 GLOBAL MARKET FOR COX-2 INHIBITORS BY PRODUCT, THROUGH 2010 ($ MILLIONS)
Table 18 U.S. MARKET FOR COX-2 INHIBITORS BY PRODUCT, THROUGH 2010 ($ MILLIONS)
Table 19 GLOBAL MARKET FOR ANTI-INFLAMMATORY TREATMENTS FOR ANKYLOSING SPONDYLITIS, THROUGH 2010 ($ MILLIONS)
Table 20 ASTHMA DRUG CATEGORIES AND SELECTED PRODUCTS
Table 21 SELECTED BRANDED ANTI-INFLAMMATORY AND BRONCHODILATING DRUGS USED TO TREAT ASTHMA
Table 22 GLOBAL MARKET FOR ASTHMA DRUGS BY CATEGORY, THROUGH 2010 ($ MILLIONS)
Table 23 GLOBAL MARKET FOR ANTI-INFLAMMATORY DRUGS USED TO TREAT ASTHMA BY CATEGORY, THROUGH 2010 ($ MILLIONS)
Table 24 U.S. MARKET FOR ASTHMA DRUGS BY CATEGORY, THROUGH 2010 ($ MILLIONS)
Table 25 GLOBAL MARKET FOR COPD DRUGS BY CATEGORY, THROUGH 2010 ($ MILLIONS)
Table 26 GLOBAL MARKET FOR ANTI-INFLAMMATORY DRUGS USED TO TREAT COPD BY CATEGORY, 2003-2010 ($ MILLIONS)
Table 27 PHOSPHODIESTERASE INHIBITORS IN PHASE II OR LATE DEVELOPMENT
Table 28 TARGETS AND APPROACHES TO THE DEVELOPMENT OF ANTI- INFLAMMATORY DRUGS TO TREAT ASTHMA
Table 29 GLOBAL MARKET FOR ANTI-INFLAMMATORY TREATMENTS FOR INFLAMMATORY BOWEL DISEASE BY CATEGORY, THROUGH 2010 ($ MILLIONS)
Table 30 BIOLOGICAL RESPONSE MODIFIERS IN PHASE II OR LATER DEVELOPMENT FOR THE TREATMENT OF CROHNS DISEASE
Table 31 GLOBAL MARKET FOR ANTICYTOKINE ANTI- INFLAMMATORY TREATMENTS FOR MULTIPLE SCLEROSIS, THROUGH 2010 ($ MILLIONS)
Table 32 GLOBAL MARKET FOR ANTI-INFLAMMATORY TREATMENTS FOR PSORIASIS, BY CATEGORY, THROUGH 2010 ($ MILLIONS)
Table 33 COMMONLY USED DMARDS FOR THE TREATMENT OF RHEUMATOID ARTHRITIS
Table 34 CURRENTLY AVAILABLE BIOLOGIC PRODUCTS FOR THE TREATMENT OF RHEUMATOID ARTHRITIS
Table 35 GLOBAL MARKET FOR MARKETED TNF-ALPHA INHIBITING PRODUCTS FOR ALL INDICATIONS, THROUGH 2010 ($ MILLIONS)
Table 36 GLOBAL MARKET FOR ANTI-INFLAMMATORY TREATMENTS FOR RHEUMATOID ARTHRITIS BY CATEGORY, THROUGH 2010 ($ MILLIONS)
Table 37 GLOBAL MARKET FOR ANTI-INFLAMMATORY TREATMENTS FOR RHEUMATOID ARTHRITIS BY REGION, THROUGH 2010 ($ MILLIONS)
Table 38 PRODUCTS IN PHASE II OR LATER DEVELOPMENT FOR THE TREATMENT OF RHEUMATOID ARTHRITIS
Table 39 AMGENS ANTI-INFLAMMATORY PRODUCT PIPELINE
Table 40 BIOGEN IDECS ANTI-INFLAMMATORY PRODUCT PIPELINE
Table 41 CAMBRIDGE ANTIBODY TECHNOLOGYS ANTI-INFLAMMATORY PRODUCT PIPELINE
Table 42 GLAXOSMITHKLINES ANTI-INFLAMMATORY PRODUCT PIPELINE
Table 43 MILLENNIUMS ANTI-INFLAMMATORY MONOCLONAL ANTIBODY PRODUCT PIPELINE
Table 44 PROTEIN DESIGN LABS ANTI-INFLAMMATORY MONOCLONAL ANTIBODY PRODUCT PIPELINE
LIST OF FIGURES
Summary Figure:
Figure 1 GLOBAL MARKET FOR ANTI-INFLAMMATORY TREATMENTS BY CATEGORY, 2003-2010 ($ MILLIONS)
Figure 2 GLOBAL MARKET FOR COX-2 INHIBITORS BY PRODUCT, 2003-2010 ($ MILLIONS)
Figure 3 U.S. MARKET FOR COX-2 INHIBITORS BY PRODUCT, 2003-2010 ($ MILLIONS)
Figure 4 GLOBAL MARKET FOR ASTHMA DRUGS BY CATEGORY, 2003-2010 ($ MILLIONS)
Figure 5 GLOBAL MARKET FOR ANTI-INFLAMMATORY DRUGS USED TO TREAT ASTHMA BY CATEGORY, 2003-2010 ($ MILLIONS)
Figure 6 U.S. MARKET FOR ASTHMA DRUGS BY CATEGORY, 2003-2010 ($ MILLIONS)
Figure 7 GLOBAL MARKET FOR COPD DRUGS BY CATEGORY, 2003-2010 ($ MILLIONS)
Figure 8 GLOBAL MARKET FOR ANTI-INFLAMMATORY DRUGS USED TO TREAT COPD BY CATEGORY, 2003-2010 ($ MILLIONS)
Figure 9 ESTIMATED GLOBAL MARKET SHARE FOR ANTI-INFLAMMATORY DRUGS TO TREAT ASTHMA/COPD, BY CATEGORY, 2005 AND 2010 (%)
Figure 10 GLOBAL MARKET FOR ANTI-INFLAMMATORY TREATMENTS FOR INFLAMMATORY BOWEL DISEASE BY CATEGORY, 2003-2010 ($ MILLIONS)
Figure 11 GLOBAL MARKET FOR ANTI-INFLAMMATORY TREATMENTS FOR PSORIASIS, BY CATEGORY, THROUGH 2010 ($ MILLIONS)
Figure 12 CATEGORIES OF DRUGS USED IN CONJUNCTION WITH TNF-ALPHA INHIBITORS (%)
Figure 13 GLOBAL MARKET FOR MARKETED TNF-ALPHA INHIBITING PRODUCTS FOR ALL INDICATIONS, 2003-2010 ($ MILLIONS)
Figure 14 GLOBAL MARKET FOR ANTI-INFLAMMATORY TREATMENTS FOR RHEUMATOID ARTHRITIS BY CATEGORY, 2003-2010 ($ MILLIONS)
Figure 15 GLOBAL MARKET FOR ANTI-INFLAMMATORY TREATMENTS FOR RHEUMATOID ARTHRITIS BY REGION, 2003-2010 ($ MILLIONS)
Figure 16 ESTIMATED GLOBAL PRESCRIPTION MARKET SHARE FOR ANTI-INFLAMMATORY TREATMENTS FOR RHEUMATOID ARTHRITIS, BY CATEGORY, 2005 (%)